Fingolimod provides long-term protection in rodent models of cerebral ischemia

Annals of Neurology

Volumn 69, Issue 1, 2011, Pages 119-129

  Wei, Ying ^a   Yemisci, Muge ^a,e   Kim, Hyung Hwan ^b,c   Yung, Lai Ming ^a   Shin, Hwa Kyoung ^a,f   Hwang, Seo Kyoung ^b   Guo, Shuzhen ^a   Qin, Tao ^a   Alsharif, Nafiseh ^a   Brinkmann, Volker ^d   Liao, James K ^b   Lo, Eng H ^a   Waeber, Christian ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jungwon University   (South Korea)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HACETTEPE UNIVERSITY   (Turkey)

^f Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GLUTAMIC ACID; HYDROGEN PEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN NERVE CELL; BRAIN PROTECTION; BRAIN WATER; CELL CULTURE; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; EXCITOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PROPYLENE GLYCOLS; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STROKE;

EID: 79551495392     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22186     Document Type: Article

References (49)

1. Dirnagl U, Iadecola C, Moskowitz MA., Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-397.
2. Hannun YA, Obeid LM., Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150.
3. Karliner JS, Honbo N, Summers K, et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001; 33: 1713-1717.
4. Jin ZQ, Zhou HZ, Zhu P, et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002; 282: H1970-H1977.
5. Adachi K, Kohara T, Nakao N, et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995; 5: 853-856.
6. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
7. Tawadrous MN, Mabuchi A, Zimmermann A, Wheatley AM., Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. Transplantation 2002; 74: 602-610.
8. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
9. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
10. Man K, Ng KT, Lee TK, et al. FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant 2005; 5: 40-49.
11. Mizuta K, Ohmori M, Miyashita F, et al. Effect of pretreatment with FTY720 and cyclosporin on ischaemia-reperfusion injury of the liver in rats. J Pharm Pharmacol 1999; 51: 1423-1428.
12. Delbridge MS, Shrestha BM, Raftery AT, et al. FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury. Transplant Proc 2007; 39: 2992-2996.
13. Delbridge MS, Shrestha BM, Raftery AT, et al. Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. Transplantation 2007; 84: 187-195.
14. Kaudel CP, Frink M, Schmiddem U, et al. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration. Transplant Proc 2007; 39: 499-502.
15. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006; 290: F1516-F1524.
16. Kim H-H, Hwang S-K, Shin HK, et al. The sphingosine-1-phosphate analogue FTY720 is neuroprotective in a rodent model of brain ischemia. Stroke 2008; 39: 729
17. 3H]L-NG-nitroarginine binding after transient focal ischemia and NMDA-induced excitotoxicity in type I and type III nitric oxide synthase null mice. J Cereb Blood Flow Metab 1997; 17: 515-526.
18. Yoshida T, Waeber C, Huang Z, Moskowitz MA., Induction of nitric oxide synthase activity in rodent brain following middle cerebral artery occlusion. Neurosci Lett 1995; 194: 214-218.
19. Guo S, Arai K, Stins MF, et al. Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 2009; 40: 652-655.
20. Xia MQ, Bacskai BJ, Knowles RB, et al. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000; 108: 227-235.
21. Shin HK, Salomone S, Potts EM, et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 2007; 27: 998-1009.
22. Li Y, Chopp M, Jiang N, et al. Induction of DNA fragmentation after 10 to 120 minutes of focal cerebral ischemia in rats. Stroke 1995; 26: 1252-1257.
23. Lipton P., Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431-1568.
24. Clark WM, Lauten JD, Lessov N, et al. Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Mol Chem Neuropathol 1995; 26: 213-230.
25. Harada J, Foley M, Moskowitz MA, Waeber C., Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004; 88: 1026-1039.
26. Bermpohl D, You Z, Korsmeyer SJ, et al. Traumatic brain injury in mice deficient in Bid: effects on histopathology and functional outcome. J Cereb Blood Flow Metab 2006; 26: 625-633.
27. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
28. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008; 117: 77-93.
29. Linares G, Mayer SA., Hypothermia for the treatment of ischemic and hemorrhagic stroke. Crit Care Med. 2009; 37: S243-S249.
30. Sim-Selley LJ, Goforth PB, Mba MU, et al. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. J Neurochem 2009; 110: 1191-1202.
31. del Zoppo GJ, Becker KJ, Hallenbeck JM., Inflammation after stroke: is it harmful? Arch Neurol 2001; 58: 669-672.
32. Yilmaz G, Granger DN., Cell adhesion molecules and ischemic stroke. Neurol Res 2008; 30: 783-793.
33. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278: 47281-47290.
34. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
35. Pham TH, Baluk P, Xu Y, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 2010; 207: 17-27.
36. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005; 2: 439-448.
37. Martin M, Mory C, Prescher A, et al. Protective effects of early CD4(+) T cell reduction in hepatic ischemia/reperfusion injury. J Gastrointest Surg 2010; 14: 511-519.
38. Suleiman M, Cury PM, Pestana JO, et al. FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. Transplant Proc 2005; 37: 373-374.
39. Yilmaz G, Arumugam TV, Stokes KY, Granger DN., Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006; 113: 2105-2112.
40. Chaitanya GV, Schwaninger M, Alexander JS, Babu PP., Granzyme-b is involved in mediating post-ischemic neuronal death during focal cerebral ischemia in rat model. Neuroscience 2010; 165: 1203-1216.
41. Ding K, Blondeau N, Lai C, et al. Neuron-derived sphingosine-1-phosphate protects brain endothelial cells from ischemia-induced cell death via Akt-mediated mechanisms. Program No. 199.111. 34th Society for Neuroscience Meeting, San Diego, 2004.
42. Czech B, Pfeilschifter W, Mazaheri-Omrani N, et al. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 2009; 389: 251-256.
43. Hasegawa Y, Suzuki H, Sozen T, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 2010; 41: 368-374.
44. Turski L, Huth A, Sheardown M, et al. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A 1998; 95: 10960-10965.
45. Elger B, Gieseler M, Schmuecker O, et al. Extended therapeutic time window after focal cerebral ischemia by non-competitive inhibition of AMPA receptors. Brain Res 2006; 1085: 189-194.
46. Nagayama M, Niwa K, Nagayama T, et al. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999; 19: 1213-1219. (Pubitemid 30176449)
47. Abe T, Kunz A, Shimamura M, et al. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab 2009; 29: 66-72.
48. Wang Y, Thiyagarajan M, Chow N, et al. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 2009; 40: 1864-1869.
49. Zlokovic BV, Zhang C, Liu D, et al. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol. 2005; 58: 474-477.